Sort   by:  
 Page size 
UnknownMultiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans.
Not available
S-EPMC4572072 | biostudies-literature
UnknownEffects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trial.
Not available
S-EPMC12274867 | biostudies-literature
UnknownA global genetic interaction map of a human cell reveals conserved principles of genetic networks.
Not available
S-EPMC12236771 | biostudies-literature
UnknownEffects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial.
Not available
S-EPMC7615591 | biostudies-literature
UnknownImpact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial.
Not available
S-EPMC7618536 | biostudies-literature
UnknownFrailty, Multimorbidity, and Polypharmacy: Exploratory Analyses of the Effects of Empagliflozin from the EMPA-KIDNEY Trial.
Not available
S-EPMC11390031 | biostudies-literature
UnknownCanadian Surgery Forum.
Not available
S-EPMC3432251 | biostudies-literature
UnknownEmpagliflozin in Patients with Chronic Kidney Disease.
Not available
S-EPMC7614055 | biostudies-literature
UnknownEffects of icosapent ethyl according to baseline residual risk in patients with atherosclerotic cardiovascular disease: results from REDUCE-IT.
Not available
S-EPMC11873788 | biostudies-literature
UnknownIdentification of seven new prostate cancer susceptibility loci through a genome-wide association study.
Not available
S-EPMC2846760 | biostudies-literature
Sort   by:  
 Page size